Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/DLG5_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/DLG5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DLG5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DLG5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DLG5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DLG5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DLG5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DLG5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00612457 | Prostate | BPH | establishment or maintenance of bipolar cell polarity | 17/3107 | 49/18723 | 1.60e-03 | 9.32e-03 | 17 |
GO:00605415 | Prostate | BPH | respiratory system development | 50/3107 | 203/18723 | 2.09e-03 | 1.17e-02 | 50 |
GO:00609992 | Prostate | BPH | positive regulation of dendritic spine development | 15/3107 | 42/18723 | 2.14e-03 | 1.19e-02 | 15 |
GO:19024143 | Prostate | BPH | protein localization to cell junction | 27/3107 | 94/18723 | 2.25e-03 | 1.24e-02 | 27 |
GO:00016563 | Prostate | BPH | metanephros development | 25/3107 | 85/18723 | 2.25e-03 | 1.24e-02 | 25 |
GO:00451977 | Prostate | BPH | establishment or maintenance of epithelial cell apical/basal polarity | 15/3107 | 44/18723 | 3.59e-03 | 1.83e-02 | 15 |
GO:00353295 | Prostate | BPH | hippo signaling | 14/3107 | 40/18723 | 3.68e-03 | 1.85e-02 | 14 |
GO:00343328 | Prostate | BPH | adherens junction organization | 16/3107 | 49/18723 | 4.35e-03 | 2.14e-02 | 16 |
GO:00604413 | Prostate | BPH | epithelial tube branching involved in lung morphogenesis | 11/3107 | 29/18723 | 4.82e-03 | 2.29e-02 | 11 |
GO:1901890 | Prostate | BPH | positive regulation of cell junction assembly | 28/3107 | 104/18723 | 5.18e-03 | 2.43e-02 | 28 |
GO:00224085 | Prostate | BPH | negative regulation of cell-cell adhesion | 46/3107 | 196/18723 | 7.95e-03 | 3.47e-02 | 46 |
GO:00421299 | Prostate | BPH | regulation of T cell proliferation | 41/3107 | 171/18723 | 8.09e-03 | 3.52e-02 | 41 |
GO:00017386 | Prostate | BPH | morphogenesis of a polarized epithelium | 25/3107 | 94/18723 | 9.36e-03 | 3.98e-02 | 25 |
GO:00706639 | Prostate | BPH | regulation of leukocyte proliferation | 55/3107 | 245/18723 | 1.02e-02 | 4.29e-02 | 55 |
GO:004209810 | Prostate | BPH | T cell proliferation | 46/3107 | 199/18723 | 1.05e-02 | 4.39e-02 | 46 |
GO:00508072 | Prostate | BPH | regulation of synapse organization | 48/3107 | 211/18723 | 1.23e-02 | 4.94e-02 | 48 |
GO:00353314 | Prostate | BPH | negative regulation of hippo signaling | 6/3107 | 13/18723 | 1.24e-02 | 4.94e-02 | 6 |
GO:000716317 | Prostate | Tumor | establishment or maintenance of cell polarity | 74/3246 | 218/18723 | 2.00e-09 | 8.86e-08 | 74 |
GO:003090115 | Prostate | Tumor | midbrain development | 36/3246 | 90/18723 | 3.15e-07 | 7.14e-06 | 36 |
GO:003432915 | Prostate | Tumor | cell junction assembly | 113/3246 | 420/18723 | 4.94e-07 | 1.07e-05 | 113 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DLG5 | SNV | Missense_Mutation | | c.2146N>C | p.Val716Leu | p.V716L | Q8TDM6 | protein_coding | tolerated(0.55) | benign(0.005) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
DLG5 | SNV | Missense_Mutation | rs750819054 | c.1496N>A | p.Arg499Gln | p.R499Q | Q8TDM6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
DLG5 | SNV | Missense_Mutation | rs200259340 | c.2038G>A | p.Asp680Asn | p.D680N | Q8TDM6 | protein_coding | tolerated(0.39) | probably_damaging(1) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DLG5 | SNV | Missense_Mutation | novel | c.3988N>C | p.Val1330Leu | p.V1330L | Q8TDM6 | protein_coding | tolerated(0.14) | benign(0.071) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
DLG5 | SNV | Missense_Mutation | rs372158883 | c.1354N>A | p.Glu452Lys | p.E452K | Q8TDM6 | protein_coding | tolerated(0.17) | possibly_damaging(0.795) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343N>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343G>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343G>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343N>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343N>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |